This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Hemispherx Not Among 4 to Get H1N1 Flu Contracts

Hemispherx Biopharma (HEB) has been shut out of the U.S. government's efforts to stockpile vaccine against the H1N1 flu.

Four companies were awarded contracts Monday totaling just under $900 million to supply ingredients for a potential H1N1 vaccine. U.S. Health and Human Services Secretary Kathleen Sebelius announced the contracts, which went to Novartis (NVS), GlaxoSmithKline (GSK), Sanofi-Aventis (SNY) and AztraZeneca (AZN).

Hemispherx wasn't necessarily in the running for a U.S. flu contract, but the company has sought, in recent weeks, to promote itself to investors as a player in the global effort to develop an effective vaccine against the latest strain of the flu.

Hemispherx CEO Bill Carter claims international partners, including vaccine makers in Japan, are interested in using Hemispherx's drug Ampligen as an adjuvant flu vaccine booster.

In an interview with a penny-stock promoter published last month, Carter said, in reference to Ampligen: "The highest level of the Japanese government and public medical community is now focused exclusively on our product. They stopped working on all other adjuvants (boosters) and are only working with this one because they've found that it enhances the vaccines by 100 fold."

But Hemispherx hasn't announced a single flu contract to date; nor has the company provided any independent corroboration of its claims that partners are actively working today to develop Ampligen as a vaccine adjuvant.

What the company has done, instead, is recycle old clinical data for use in new press releases touting Ampligen's use as a flu vaccine booster.

Carter's talk of Ampligen and flu vaccines is more likely yet another attempt to divert attention away from the problems the company is having getting Ampligen approved as a treatment for chronic fatigue syndrome (CFS).

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs